The latest biopharma awards press releases and news
IMAPAC Applauds WuXi Biologics on Winning Two Awards at the Asia Pacific Bioprocessing Excellence Awards 2023
Singapore, April 7, 2023 – IMAPAC, a leading event management company specializing in the biopharmaceutical industry, congratulates WuXi Biologics on receiving the “Best Contract Development and Manufacturing Organization Award” and the “Bioprocessing Excellence in Greater China Region Award” at the 2023 APAC Bioprocessing Excellence Awards (ABEA) ceremony. This marks the sixth time that WuXi Biologics has been recognized by IMAPAC.
ABEA 2023 acknowledges the exceptional achievements of top biomanufacturing companies and celebrates the innovation and leadership of industry trend-setters. Each year, ABEA 2023 shortlists 5-7 nominees under each award category, and the final winners are determined by voting results from the bioprocessing community.
WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) that provides end-to-end solutions for partners to discover, develop, and manufacture biologics for patients worldwide. In 2022, WuXi Biologics supported its global clients in obtaining 123 Investigational New Drug (INDs) approvals, including a novel RNA product. The company’s global manufacturing network currently supports 17 commercial biologics and vaccines, with the capacity to support more commercial projects across its 14 drug substance (DS) manufacturing facilities and 9 drug product (DP) fill sites.
“We congratulate WuXi Biologics on their outstanding achievements and contributions to the biopharmaceutical industry,” said Aloysius Chong, Director of IMAPAC Biopharma Awards. “Their dedication to quality and innovation in bioprocessing is evident in the numerous regulatory inspections they have passed and the commercial licenses they have been granted. We are thrilled to see WuXi Biologics once again receive recognition for their exceptional work, and we look forward to their continued success in the future.”
Check out WuXi Biologics’ Press Release on their two awards here.
IMAPAC is a leading event management company specializing in the biopharmaceutical industry. With over 12 years of experience, IMAPAC has successfully organized more than 50 industry events, attracting over 15,000 participants from around the world. IMAPAC’s events are renowned for their high-quality content, prestigious speakers, and networking opportunities.
IMAPAC has successfully held the Asia-Pacific Bioprocessing Excellence Awards 2023, recognizing outstanding achievements and contributions in bioprocessing. The awards ceremony attracted over 80 participants from more than 40 biopharmaceutical companies across the Asia-Pacific region, with 53 categories such as Best Biomanufacturing Team and Best Emerging Biotech Company.
The Biopharma Logistics and Supply Chain Excellence Awards (BLSA) 2023 APAC recognized outstanding achievements in biologistics across Asia at their 2023 ceremony, held alongside the 7th BioLogistics World Asia event. The awards celebrate exceptional personnel, organizations, and technologies in the industry and aim to inspire future innovators.
The Biopharma R&D and Clinical Trials Awards (BRCTA) 2023 recognized exceptional Asian clinical trials leaders, organizations, and technologies over the past year. The awards include various categories such as Excellence Awards, Individual Awards, and Team Awards, identifying the best of the best in the industry.